Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Trinity Innovation Bioventure Singapore (TIBS) is a licensed biomed venture capital fund established in 2018 and headquartered in Singapore. The firm is part of the Trinity Innovation Fund group and focuses on innovation and value investment within the biomed sector, particularly in Asian markets. TIBS has built a reputation for identifying emerging innovations and opportunities for new drug development, leveraging its deep understanding of the Asian markets.
The firm is managed by a team with extensive experience in venture capital and biotechnology investments. TIBS has received recognition as the "Most Innovative Biomed Venture Capital Fund 2023 – Asia" from Wealth & Finance International, underscoring its commitment to advancing the biomed sector.
TIBS primarily invests in the biomed sector, emphasizing innovation and value creation. The firm targets early-stage companies, from incubation through Series A funding, with a focus on platform-driven biotech that demonstrates breakthrough technology and differentiated scientific merit. TIBS aims to address unmet medical needs through innovative therapeutics.
Geographically, TIBS concentrates on Asian markets, particularly Singapore, Beijing, and Shanghai, while also maintaining some global exposure. The firm seeks to identify emerging innovations and opportunities for new drug development, ensuring that its investments align with its thesis of commercial value and scientific merit.
TIBS has invested in a variety of biotech companies, showcasing its commitment to the biomed sector. Notable portfolio companies include:
Jack Yin Zheng — Founding Partner; brings extensive experience in venture capital and a background in pharmaceuticals and academia. He holds a PhD in Science from the National University of Singapore.
David Wang Xukun — Partner; has 20 years of experience in biomedical research and pharmaceuticals. He holds a PhD in Biological Sciences and an MBA from the National University of Singapore.
Ivan Cao — Investment Partner; possesses 20 years of experience in private equity and founded a top-tier healthcare investment fund in China.
Langdon Wu — Managing Director; has a background in Fortune 500 companies and holds an Executive MBA from the National University of Singapore.
Thomas Keller — Scientific Advisor; specializes in drug discovery and preclinical development, holding a PhD in organic chemistry.
To pitch TIBS, founders should use the official website's contact form. A well-structured pitch deck should include details about the technology, market opportunity, and team background. Response times may vary, but founders are encouraged to follow up if they do not receive a timely reply.
In 2023, Trinity Innovation Bioventure Singapore was awarded the title of "Most Innovative Biomed Venture Capital Fund 2023 – Asia" by Wealth & Finance International, highlighting its impact in the biomed sector.
Additionally, TIBS has been involved in significant financing rounds and partnerships with companies such as Avadel Pharmaceuticals, Epigenic Therapeutics, and Argo Biopharma, showcasing its active role in the biotech investment landscape.
What are TIBS's investment criteria?
TIBS invests in early-stage biotech companies that demonstrate innovation and value creation. The firm focuses on platform-driven biotech with breakthrough technology and commercial viability.
How can I pitch to TIBS?
Founders can pitch their startups through the official website at trinity-fund.com.sg. It is advisable to include detailed information about the technology, market potential, and team in the pitch deck.
What makes TIBS different from other VCs?
TIBS has a unique focus on the Asian biomed sector, particularly Singapore, Beijing, and Shanghai. Its dual corridor strategy bridges Southeast Asia and Greater China, providing a differentiated positioning in the biotech ecosystem.
What is TIBS's geographic scope?
The firm primarily focuses on Asian markets, especially Singapore, Beijing, and Shanghai, while also having some global exposure.
What is TIBS's post-investment involvement?
TIBS actively supports its portfolio companies through mentorship, operational support, and follow-on investments, leveraging the team's extensive experience in venture capital and biotechnology.
What is the fund size and check size?
While specific fund size and check size details are not publicly disclosed, TIBS focuses on early-stage investments, typically ranging from incubation to Series A funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.